Coirradiation of the heart enhances risk and severity of radiation-induced lung toxicity through an unknown mechanism. We show that irradiation of heart, lung, or both independently induces specific cardiac dysfunction and pulmonary vascular damage, mutually enhancing each other. These results show that treatment of thoracic cancer with radiation therapy requires optimization for both pulmonary and cardiac function to reduce the risk of toxicity.
Summary
Coirradiation of the heart enhances risk and severity of radiation-induced lung toxicity through an unknown mechanism. We show that irradiation of heart, lung, or both independently induces specific cardiac dysfunction and pulmonary vascular damage, mutually enhancing each other. These results show that treatment of thoracic cancer with radiation therapy requires optimization for both pulmonary and cardiac function to reduce the risk of toxicity.
Introduction: The risk of early radiation-induced lung toxicity (RILT) limits the dose and efficacy of radiation therapy of thoracic tumors. In addition to lung dose, coirradiation of the heart is a known risk factor in the development RILT. The aim of this study was to identify the underlying physiology of the interaction between lung and heart in thoracic irradiation. Methods and Materials: Rat hearts, lungs, or both were irradiated to 20 Gy using high-precision proton beams. Cardiopulmonary performance was assessed using breathing rate measurements and F 18 -fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET) scans biweekly and left-and right-sided cardiac hemodynamic measurements and histopathology analysis at 8 weeks postirradiation. Results: Two to 12 weeks after heart irradiation, a pronounced defect in the uptake of 18 F-FDG in the left ventricle (LV) was observed. At 8 weeks postirradiation, this coincided with LV perivascular fibrosis, an increase in LV end-diastolic pressure, and pulmonary edema in the shielded lungs. Lung irradiation alone not only increased pulmonary artery pressure and perivascular edema but also induced an increased LV relaxation time. Combined irradiation of lung and heart induced pronounced increases in LV end-diastolic pressure and relaxation time, in addition to an increase in right ventricle end-diastolic pressure, indicative of biventricular diastolic dysfunction. Moreover, enhanced pulmonary edema, inflammation and fibrosis were also observed. Conclusions: Both lung and heart irradiation cause cardiac and pulmonary toxicity via different mechanisms. Thus, when combined, the loss of cardiopulmonary performance is intensified further, explaining the deleterious effects of heart and lung coirradiation. Our
Introduction
For many thoracic tumors treated with radiation therapy, dose escalation is expected to improve local control. However, the dose that can be administered safely is limited by the risk of potentially lethal radiation-induced lung toxicity (RILT). In a clinical situation, RILT manifests as respiratory distress and changes on thorax radiograph and computed tomography (1) .
Several treatment-related factors such as the radiation dose and amount of irradiated lung tissue correlate with the risk of developing RILT (1) . In addition to lung tissue, part of the heart is often also irradiated (2) . Although the heart is generally considered not to be functionally affected early after irradiation, early radiationinduced effects have been reported in animal (3) and clinical (4) studies. Coirradiation of the heart was also shown to enhance the risk of RILT both in animal studies (5, 6) and in patients with non-small cell lung cancer (NSCLC) (2) . Therefore, the contribution of the heart as well as the lung in the development of early RILT should be taken into account for treatment optimization. Until now, however, the mechanism through which this interaction takes place is not known.
Recently, it was shown in rats that lung irradiation induces pulmonary hypertension and right ventricle hypertrophy in an irradiated-volume-dependent manner (7) . Pulmonary hypertension can contribute to cardiac dysfunction (8) . The possible contribution of radiation-induced pulmonary hypertension in cardiac damage was suggested in the early 1990s in a canine model (9) ; however, the underlying physiological changes remain unknown.
Taken together, these observations indicate that lung irradiation can cause changes in the heart and that heart irradiation can cause changes in the lung, leading collectively to physiological changes in the cardiopulmonary system. Therefore, in this study we investigated whether physiological changes caused by irradiation of the lung, heart, or both can explain their interaction in the development of radiation-induced cardiopulmonary dysfunction. 
Methods and Materials Animals

Irradiation technique
Rat hearts, lungs, or both were irradiated (single fraction) using a high-precision proton beam (150 MeV) as described previously (6) . Briefly, high-energy protons were used, leading to uniform dose distributions in the longitudinal direction (1%) with sharp lateral field edges (20%-80% isodose distance: 1 mm). This steep penumbra (0.9-1.1 mm) facilitates the separate irradiation of lung and heart required for dissecting the individual contributions of each on tissue damage and dysfunction. The rats were irradiated under anesthesia (isoflurane) and suspended from their incisors. The isodose curves of the irradiation portals (Supplementary Table  S1 ) are shown in Fig. 1 .
Breathing rate assay
In preclinical studies, breathing rate (BR) is considered a surrogate measure for pulmonary function (7) . The increase of the postirradiation BR relative to the mean BR in weeks 0-2 after irradiation was used as an indicator of early pulmonary dysfunction (7) . Current data (nZ5/group) were combined with historical data (5, 6).
Radiology
Electrocardiogram (ECG)-gated cardiac 18 F-fluoridedeoxyglucose positron emission tomography ( 18 F-FDG-PET) scans were used to investigate whether heart irradiation induces cardiac changes. Reduction in 18 F-FDG uptake of the left ventricle (LV) was scored (Supplementary Table S2 ; nZ6/group) and reported as LV 18 F-FDG uptake defect.
Hemodynamic measurements
LV or right ventricle (RV) hemodynamic measurements were carried out to investigate cardiac physiological changes 8 weeks after irradiation. For LV hemodynamic measurement (nZ5/ group), a pressure catheter was introduced via the carotid artery and guided through the aorta into the LV to obtain LV enddiastolic pressure (LVEDP) and Tau (LV relaxation constant). RV pressure and pulmonary artery pressure (nZ4/group) were recorded from RV hemodynamic measurement (7) . Wet lungs were weighed to check if they were edematous. The heart was divided into atria, ventricles, and septum and weighed separately to assess RV hypertrophy (7).
Morphological changes
Pulmonary edema, inflammation and fibrosis, as well as cardiac perivascular fibrosis, were assessed in samples from the irradiated and the shielded lung and heart (n!4/group). Pulmonary edema was assessed using hematoxylin and eosin staining and semiquantitative scoring of interstitial and perivascular edema. For interstitial edema, scores from 0-3 were given reflecting the severity of the damage to the interstitial tissue and the amount of affected tissue with or without interstitial infiltrate. For perivascular edema, scores from 0-2 were given to show the severity of the edema around vessels. At least 5 large vessels (>100 mm) and 20 small vessels (<100 mm) with or without perivascular infiltrate were scored. Using hematoxylin and eosin staining, pulmonary parenchymal inflammation was scored from 0-3 on the basis of the number of inflammatory cells in the lung parenchyma. For fibrosis, Masson trichrome staining was used. Pulmonary parenchymal fibrosis was scored 0-3 based on the amount of deposited collagen. Cardiac perivascular fibrosis was quantified by calculating the ratio of the fibrosis area surrounding the vessel to the total vessel area using an image analysis system (CZ KS400; Imaging Associates, Bicester, United Kingdom). For this, at least 20 vessels were examined, and, depending on the amount of vessels, the average results per group were obtained from LVs of at least 4 rats.
Quantitative polymerase chain reaction
Total RNA was extracted from the phosphate buffered salineperfused rat LVs (nZ4/group), and cDNA was generated subsequently according to the manufacturers' protocols. Bio-Rad IQTM SYBR Veenendaal, The Netherlands Green Supermix was used to perform amplifications in a Bio-Rad IQ iCycler machine as described by the manufacturer. The following primers were used to amplify fibronectin: 5 0 -agaccatacctgccgaatgtag and gagagcttcttgtcctgtagag. The mRNA levels were normalized using 36B4 (ribosomal) primers with the sequences 5 0 -gttgcctcagtgcctcactc and 5 0 -gcagccgcaaatgcagatgg.
Statistical analysis
Differences between groups were tested by comparing the functional and physiological parameters of the groups using 1-way analysis of variance with Bonferroni post hoc analysis to correct for multiple comparisons. For morphologic assessments, 
Results
Radiation induces early cardiac damage
To confirm the interaction between lungs and heart on radiationinduced pulmonary dysfunction (5), we investigated the BR after partial irradiation of the rat lung, with or without irradiation of the heart. Coirradiation of the heart induced a pronounced BR increase ( Supplementary Fig. S1 ). This suggests that heart irradiation may induce early subclinical heart damage that manifests only in combination with lung irradiation resulting in an aggravated reduction in lung function (5) . To determine whether heart irradiation induces early cardiac damage, cardiac metabolism was assessed by 18 F-FDG-PET scans. Scans were taken biweekly for 12 weeks after irradiation of the heart and the adjacent lung tissue (25% of the lung) with a dose below and above 18 Gy, the threshold for lung-heart interaction (6). Indeed, a significant defect in 18 F-FDG uptake was observed in the LVs at both dose levels (Fig. 2, P< .01 H þ 25% L, 16 Gy vs control and P<.001 H þ 25% L, 25 Gy vs control). Physiology of heart-lung interaction in thoracic irradiation e641
Heart irradiation induces cardiac fibrosis and myocardial damage
To investigate the origin of these metabolic changes, we investigated the morphology of the LVs. Immunohistochemical staining (Fig. 3a) and morphologic quantification (Fig. 3b, P<.01) showed pronounced perivascular fibrosis in the irradiated LVs (20 Gy). Moreover, in irradiated LVs, a relative increase in fibronectin mRNA expression, a well-established profibrotic gene (10), was observed (Fig. 3c, P<.05) .
Aside from perivascular fibrosis, contraction bands (Fig. 3d , yellow arrows) were observed in the myocardium of the irradiated LVs located predominately in endocardium and epicardium.
Heart irradiation induces left ventricle diastolic dysfunction
Myocardial damage and perivascular fibrosis are known to be an important pathophysiological processes contributing to diastolic dysfunction by impairing cardiac relaxation (11, 12) . Therefore, we next investigated whether the observed histopathology and metabolic changes translate into changes in cardiac function. To this end, LV hemodynamics were assessed. Heart irradiation (20 Gy) induced a pronounced elevation of the LVEDP (Fig. 4a , P<.05). Moreover, pericardial effusion was observed in 2 of 9 irradiated hearts. Next we determined to what extent radiationinduced physiological changes can be explained by LV morphologic changes, by correlating LV perivascular fibrosis with LVEDP. The perfect correlation ( Supplementary Fig. S2a ) indicated that LV diastolic dysfunction can be fully explained by changes in cardiac vasculature.
Heart irradiation enhances lung tissue damage
Because diastolic dysfunction is known to promote pulmonary edema (13) , it may be the mechanism through which heart irradiation induces pulmonary dysfunction. If so, this would lead to pulmonary edema in shielded lung tissue. Morphologic analysis showed significant pulmonary interstitial edema after heart irradiation (Fig. 5a, P<.001) . Moreover, the wet weight of the lungs was higher when the hearts were irradiated ( Supplementary  Fig. S3 ). Also in 3 of 9 rats with irradiated hearts (20 Gy), pleural effusion was observed. A strong correlation between LVEDP and pulmonary interstitial edema ( Supplementary  Fig. S2a ) suggests that LV diastolic dysfunction induces secondary lung damage. In addition to pulmonary edema, morphological evaluation revealed more pulmonary parenchymal inflammation and fibrosis (Fig 5b, P<.001 and P<.01 respectively) when the heart was coirradiated.
Combined lung and heart irradiation: double trouble
If irradiation of heart and lung both have a common consequence, this would explain the observed interaction between them. Importantly, irradiation of 50% of lung (20 Gy) has also been shown to induce not only pulmonary edema (Fig. 5a , Supplementary Fig. S3 , P<.05) and inflammation (Fig. 5b , P<.05) but also affect the heart due to increased pulmonary tension, leading to RV systolic pressure overload and RV hypertrophy (7) (Supplementary Fig. S4 ). Because all of these factors are known to cause LV dysfunction (8), we investigated LV function after lung irradiation. Indeed, significant elevation of tau (Fig. 4b, P<.05 ) was observed. A strong correlation among pulmonary hypertension, perivascular edema, and tau ( Supplementary Fig. S2b ) indicates that secondary cardiac damage can be explained by radiation-induced lung damage.
We next investigated whether combining these effects by simultaneous irradiation of both organs results in enhanced response. To this end, cardiac performance was assessed after heart þ 50% lung irradiation (20 Gy). Significant elevation of both LVEDP (Fig. 4a , P<.01) and tau (Fig. 4b, P<.05 ), in addition to perivascular fibrosis (Fig. 3b , P<.001) were observed in this setting. Furthermore, enhanced wet lung weight increase ( Supplementary Fig. S2 , P<.001), pulmonary interstitial edema (Fig. 5a , P<.001), perivascular edema (Fig. 5a , P<.05), parenchymal inflammation (Fig. 5b, P<.001) , fibrosis (Fig. 5b , P<.001), and pleural effusion (5 of 9 rats) were observed in the group that received combined lung and heart irradiation. In addition to LV diastolic dysfunction, pulmonary edema may also develop from RV diastolic dysfunction, because it may be induced by pulmonary hypertension ( Supplementary Fig. S4a and S4b). Consistent with this, we also observed a pronounced increase in RV diastolic pressure (Fig. 6, P<.001 ).
Discussion
Our results document the physiology of how cardiac and pulmonary damage can mutually influence cardiopulmonary function. We observed that heart irradiation directly affects cardiac vasculature and myocardium and therefore increases end-diastolic pressure, leading to LV diastolic dysfunction, which promotes pulmonary interstitial edema. Lung irradiation indirectly impairs LV diastolic function through radiation-induced pulmonary hypertension, pulmonary perivascular edema, and the resultant effect on LV relaxation time. Combined lung and heart irradiation enhances cardiac diastolic dysfunction via both mechanisms, which may result in biventricle dysfunction, explaining the observed aggravated cardiopulmonary dysfunction. We propose that cardiac dysfunction, either originating directly from heart irradiation or indirectly caused by lung irradiation, may be an important factor causing or enhancing cardiopulmonary toxicity after thoracic radiation therapy.
Consistent with our observations, changes in cardiac 18 F-FDG uptake were observed in patients with esophageal cancer 3-9 months postradiation therapy. Moreover, these changes correlated 4 . Left ventricular hemodynamics after heart or lung irradiation, or both. Significant increases in LV end-diastolic pressure (LVEDP) were observed in H þ 25% L and H þ 50% L groups (a), whereas elevation of tau was observed in 50% L and H þ 50% L groups (b). ***P<.001, **P<.01, *P<.05 compared with control. Data are presented as mean AE SEM.
with elevated plasma levels of brain natriuretic peptide, a known marker of cardiac diastolic dysfunction in patients with acute dyspnea (14) .
In preclinical studies on RILT, BR increase is often considered a surrogate measurement of radiation pneumonitis (1). Indeed, these BR changes may reflect a reduced diffusion capacity due to parenchymal damage such as alveolitis. In addition, it may reflect decreased ventilation efficiency as a consequence of reduced perfusion, a symptom frequently observed in patients with pulmonary hypertension and edema (7) . Radiation-induced pulmonary hypertension was shown to contribute to BR changes not only in single irradiation dose preclinical studies (7, 9) but also in fractionation study in a canine model (15) . Clinical symptoms of cardiac diastolic dysfunction are also predominantly respiratory in nature due to backward failure of the LV causing congestion of the pulmonary vasculature and pulmonary edema (13) . Consistent with this, cardiac dysfunction was shown to play key role in the development of BR increase in our study. Taken together, this suggests that dyspnea may originate from physiological cardiopulmonary changes such as cardiac diastolic dysfunction and pulmonary hypertension rather than parenchymal damage alone. However, to substantiate our findings, studies with fractionated dose in larger animal models or in patients should be performed.
Current practice in the optimization of the treatment of NSCLC is mainly based on the dose distribution in the lungs and the dose to spinal cord. The local control of the lung tumors could be improved to w80%-90% by increasing the tumor dose by w20% (16) . At present, however, this dose escalation is not possible in the majority of patients because of the associated risk of RILT. Importantly, in our preclinical studies, differences in tolerance dose between coirradiating and sparing of the heart were typically in the same range (5, 6) . Currently, conforming to the dose constraints of the lung often results in an increase of dose to the heart. Our present work shows that for a given lung dose, increasing dose to the heart may in fact increase the risk of RILT, thus hampering efforts for dose escalation. Therefore, adding dose constraints for the heart in the treatment optimization for NSCLC may allow dose escalation and consequently increase the local control. Recently, preclinical and clinical studies have suggested that models of RILT can be improved by accounting for the impact of dose to the heart on the risk of complications (2, 6) . However, the approach to optimally distribute dose over the lung and heart is still unclear. Because we now show that symptomatic RILT results from physiological cardiopulmonary changes, dose-response relationships of these changes such as LVEDP and pulmonary artery pressure in patients incorporating both lung and heart dosevolume variables are needed to build more accurate predictive models.
In addition to dosimetric factors, pretreatment clinical factors could be incorporated into the predictive models. Preexisting lung diseases (17) and cardiac and pulmonary comorbidity (18) are known to predict adverse effects of a treatment. More accurate models will help to identify patients with a higher risk of RILT. Notably, dose limits for the entire population is currently based on these patients, accurately identifying them increases the tolerance of the residual population, thereby allowing tumor dose escalation. The patients for whom tumor location and size prevents radiation therapy with conventional modalities are suitable candidates for dose escalation by more focalized radiation treatment modalities such as particle radiation therapy (19) . Here, the dose is more confined to the target, and coirradiation of the heart and large volumes of healthy lung tissue can be more effectively spared (19) .
Symptoms of RILT were shown not to be limited to patients with radiologic changes, nor were these changes exclusively associated with symptomatic patients (20) . Radiographically occult factors such as vascular damage (7) and cardiac damage (present results) may contribute to the development of RILT and the associated symptoms. Therefore, in addition to diagnostic tools of lung damage, (subclinical) cardiac damage should be assessed for a better assessment of RILT.
Taken together, our findings show for the first time that reducing the risk of the multiorgan complication RILT, requires specific optimization of the treatment with respect to cardiac and pulmonary dose. This may lead to the development of more accurate prediction and more effective treatment of thoracic cancers, thereby facilitating individualized dose escalation, increased local control, and improved quality of life for patients undergoing thoracic radiation therapy. Physiology of heart-lung interaction in thoracic irradiation e645
